When a PSEN2 Genetic Test Is Abnormal: What Comes Next in Dementia Testing?

Learn how a PSEN2 result shapes diagnosis, family testing, brain biomarkers, and trial choices.

An abnormal PSEN2 test means the lab found a change in PSEN2, a gene linked to early-onset Alzheimer disease. What comes next is confirming whether that change is disease-causing, then arranging neurology care, counseling, and Alzheimer biomarker testing. PSEN2 makes part of a cell protein that processes amyloid. A harmful change can drive early amyloid buildup, but the gene result alone does not diagnose dementia.

Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.

Table of Contents

Is the variant harmful or uncertain?

A lab must classify the result as pathogenic or likely pathogenic versus a variant of uncertain significance, called VUS. Only a pathogenic or likely pathogenic result can guide diagnosis or family testing. A VUS cannot guide diagnosis or predictive testing.

The eviCore Lab Management Guidelines recommend genetics review, family segregation, and database checks for uncertain results, described in the eviCore Lab Management Guidelines. Ask for the written classification, the evidence behind it, and whether re-review is planned. Bring prior test reports and a three-generation family history to that visit.

What does pathogenic PSEN2 mean?

Pathogenic PSEN2 variants cause autosomal-dominant early-onset Alzheimer disease. That means one copy can pass disease risk down a family line. These variants account for about 5% of early-onset familial cases, with typical onset from 40 to 75 years and mean disease duration of 11 years, according to the NCBI GeneReviews Alzheimer Disease Overview.

Penetrance is about 95%, yet onset varies widely. Onset has ranged from 39 to 83 years, with over 20 years variation within one family. Some carriers over age 80 remain without symptoms, so age alone does not settle risk.

How is dementia confirmed after the gene result?

A gene result points to cause, not current brain status. Confirmation needs structured cognitive, functional, and etiologic testing plus prompt neurology referral and pre- and post-test counseling.

Useful Alzheimer markers include amyloid PET, spinal-fluid amyloid and tau measures, and MRI or FDG-PET injury markers. Since May 2025, an FDA-cleared plasma Lumipulse G pTau217 to beta-amyloid 1-42 ratio can aid diagnosis in symptomatic adults 55 and older as an adjunct, not standalone screening, as reported by MedicalDaily in its report on the May 2025 FDA clearance. Practical next steps to discuss with the clinician:.

  • Schedule neurology plus genetic counseling with planned result disclosure
  • Complete memory, daily-function, medication, sleep, mood, and medical workup
  • Select biomarkers based on symptoms, age, safety, and access
  • Document advance preferences before predictive family testing proceeds

Who in the family should be tested next?

Each first-degree child of a carrier has a 50% chance of inheriting the variant. Risk also extends to siblings and wider relatives on the carrier side. Guidelines recommend testing an affected relative first when possible.

Then at-risk relatives can be offered targeted cascade testing, predictive testing, and preconception counseling. Do not test children for adult-onset risk without expert counseling. Plan who is told, when, and what support follows a positive, negative, or uncertain result.

What care and research follow a PSEN2 finding?

Make a near-term care plan for safety, work, driving, finances, and caregiver support. Keep follow-up tied to symptoms and biomarker results, not the gene result alone.

PSEN2 families should also be offered referral to the Dominantly Inherited Alzheimer Network observational study and prevention trials. That program enrolls carriers or children of carriers of PSEN1, PSEN2, or APP changes to test amyloid-removing treatments years before expected symptoms, according to the Dominantly Inherited Alzheimer Network project page. Ask neurology or genetics for a referral.


You Might Also Like

HelpDementia.com

Dementia, Alzheimer's, Caregiving & Healthy Aging Guidance

© 2026 HelpDementia.com. All rights reserved.

Educational information only. It is not medical advice and does not replace care from a qualified clinician.